Evidence on the use of progesterone in menopausal hormone therapy

References

• The NAMS 2017 Hormone Therapy Position Statement Advisory Panel. The 2017 hormone therapy position statement of the North American menopause society. Menopause 2017;24:728–53
   PubMed Web of Science ®Google Scholar
• Cordina-Duverger E, Truong T, Anger A, et al. Risk of breast cancer by type of menopausal hormone therapy: a case-control study among post-menopausal women in France. PLoS One 2013;8:e78016
   PubMed Web of Science ®Google Scholar
• Canonico M, Fournier A, Carcaillon L, et al. Postmenopausal hormone therapy and risk of idiopathic venous thromboembolism: results from the E3N cohort study. Arterioscler Thromb Vasc Biol 2010;30:340–5
   PubMed Web of Science ®Google Scholar
• Canonico M, Oger E, Plu-Bureau G, et al. Hormone therapy and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration and progestogens: the ESTHER study. Circulation 2007;115:840–5
   PubMed Web of Science ®Google Scholar
• Olie V, Plu-Bureau G, Conard J, Horellou MH, Canonico M, Scarabin PY. Hormone therapy and recurrence of venous thromboembolism among postmenopausal women. Menopause 2011;18:488–93
   PubMed Web of Science ®Google Scholar
• Canonico M, Carcaillon L, Plu-Bureau G, et al. Postmenopausal hormone therapy and risk of stroke: impact of the route of estrogen administration and type of progestogen. Stroke 2016;47:1734–41
   PubMed Web of Science ®Google Scholar
• TherapeuticsMD. TXMD Overview November 2017. Available from: https://ir.therapeuticsmd.com/static-files/c2e7f9d1-d150-4b4d-8703-e4f5c362169c [last accessed 7 Jan 2018]
   Google Scholar
• Eden JA, Hacker NF, Fortune M. Three cases of endometrial cancer associated with bioidentical hormone replacement therapy. Med J Aust 2007;187:244–5
   PubMed Web of Science ®Google Scholar
• Davis R, Batur P, Thacker HL. Risks and effectiveness of compounded bioidentical hormone therapy: a case series. J Womens Health (Larchmt) 2014;23:642–8
   PubMed Web of Science ®Google Scholar
• Dezman VL, Gersak MZ, Gersak K. Two case of atypical endometrial hyperplasia associated with “bioidentical” hormone replacement therapy: IGCS-0084 uterine cancer, including sarcoma. Int J Gynecol Cancer 2015;25(Suppl 1):71
   PubMed Web of Science ®Google Scholar
• Blumel JE, Chedraui P, Baron G, et al. A large multinational study of vasomotor symptom prevalence, duration, and impact on quality of life in middle-aged women. Menopause 2011;18:778–85
   PubMed Web of Science ®Google Scholar
• Hunter MS, Gentry-Maharaj A, Ryan A, et al. Prevalence, frequency and problem rating of hot flushes persist in older postmenopausal women: impact of age, body mass index, hysterectomy, hormone therapy use, lifestyle and mood in a cross-sectional cohort study of 10,418 British women aged 54-65. BJOG 2012;119:40–50
   PubMed Web of Science ®Google Scholar
• Whiteley J, Wagner JS, Bushmakin A, Kopenhafer L, Dibonaventura M, Racketa J. Impact of the severity of vasomotor symptoms on health status, resource use, and productivity. Menopause 2013;20:518–24
   PubMed Web of Science ®Google Scholar
• Stute P, Neulen J, Wildt L. The impact of micronized progesterone on the endometrium: a systematic review. Climacteric 2016;19:316–28
   PubMed Web of Science ®Google Scholar
• Writing Group for the PEPI Trial. Effects of hormone replacement therapy on endometrial histology in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) trial. JAMA 1996;275:370–5
   PubMed Web of Science ®Google Scholar
• Pickar JH, Yeh IT, Wheeler JE, Cunnane MF, Speroff L. Endometrial effects of lower doses of conjugated equine estrogens and medroxyprogesterone acetate: two-year substudy results. Fertil Steril 2003;80:1234–40
   PubMed Web of Science ®Google Scholar
• Chlebowski RT, Anderson GL, Sarto GE, et al. Continuous combined estrogen plus progestin and endometrial cancer: the women’s health initiative randomized trial. J Natl Cancer Inst 2016;108:dvj350
   Google Scholar
• Allen NE, Tsilidis KK, Key TJ, et al. Menopausal hormone therapy and risk of endometrial carcinoma among postmenopausal women in the European prospective investigation into cancer and nutrition. Am J Epidemiol 2010;172:1394–403
   PubMed Web of Science ®Google Scholar
• Fournier A, Dossus L, Mesrine S, et al. Risks of endometrial cancer associated with different hormone replacement therapies in the E3N cohort, 1992-2008. Am J Epidemiol 2014;180:508–17
   PubMed Web of Science ®Google Scholar
• Moyer DL, Felix JC, Kurman RJ, Cuffie CA. Micronized progesterone regulation of the endometrial glandular cycling pool. Int J Gynecol Pathol 2001;20:374–9
   PubMed Web of Science ®Google Scholar
• Darj E, Nilsson S, Axelsson O, Hellberg D. Clinical and endometrial effects of oestradiol and progesterone in post-menopausal women. Maturitas 1991;13:109–15
   PubMed Web of Science ®Google Scholar
• Prometrium® (Progesterone, USP) Prescribing Information. Catalent Pharma Solutions. St. Petersburg, FL. 2011
   Google Scholar
• US Department of Health and Human Services (FDA). Guidance for Industry: Estrogen and estrogen/progestin drug products to treat vasomotor symptoms and vulvar and vaginal atrophy symptoms–recommendations for clinical evaluation. January 2003. Available from: http://www.fda.gov/downloads/Drugs/DrugSafety/informa-tionbyDrugClass/UCM135338.pdf [last accessed Aug 2015]
   Google Scholar
• European Medicines Agency. Guideline on clinical investigation of medicinal products for hormone replacement therapy of oestrogen deficiency symptoms in postmenopausal women. October 2005. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003348.pdf [last accessed Dec 2016]
   Google Scholar
• Lobo RA, Archer DF, Kagan R, et al. A 17β-estradiol-progesterone oral capsule for vasomotor symptoms in postmenopausal women: a randomized controlled trial. Obstet Gynecol 2018, In press
   Google Scholar
• Cicinelli E, de Ziegler D, Bulletti C, Matteo MG, Schonauer LM, Galantino P. Direct transport of progesterone from vagina to uterus. Obstet Gynecol 2000;95:403–6
   PubMed Web of Science ®Google Scholar
• Ficicioglu C, Gurbuz B, Tasdemir S, Yalti S, Canova H. High local endometrial effect of vaginal progesterone gel. Gynecol Endocrinol 2004;18:240–3
   PubMed Web of Science ®Google Scholar
• Hodis HN, Mack WJ, Henderson VW, et al. Vascular effects of early versus late postmenopausal treatment with estradiol. N Engl J Med 2016;374:1221–31
   PubMed Web of Science ®Google Scholar
• de Ziegler D, Ferriani R, Moraes LA, Bulletti C. Vaginal progesterone in menopause: crinone 4% in cyclical and constant combined regimens. Hum Reprod 2000;15(Suppl 1):149–58
   PubMed Web of Science ®Google Scholar
• Ross D, Cooper AJ, Pryse-Davies J, Bergeron C, Collins WP, Whitehead MI. Randomized, double-blind, dose-ranging study of the endometrial effects of a vaginal progesterone gel in estrogen-treated postmenopausal women. Am J Obstet Gynecol 1997;177:937–41
   PubMed Web of Science ®Google Scholar
• Cicinelli E, de Ziegler D, Galantino P, et al. Twice-weekly transdermal estradiol and vaginal progesterone as continuous combined hormone replacement therapy in postmenopausal women: a 1-year prospective study. Am J Obstet Gynecol 2002;187:556–60
   PubMed Web of Science ®Google Scholar
• Noe G, Sitruk-Ware R, Zegers-Hochschild F, et al. Endometrial effect of progesterone delivered by vaginal rings in estrogen-treated postmenopausal women. Climacteric 2010;13:433–41
   PubMed Web of Science ®Google Scholar
• Ferrero S, Gerbaldo D, Fulcheri E, Cristoforoni P. Vaginal micronized progesterone in continuous hormone replacement therapy. A prospective randomized study. Minerva Ginecol 2002;54:519–30
   PubMedGoogle Scholar
• Mirkin S, Navarro F, Archer DF. Hormone therapy and endometrial angiogenesis. Climacteric 2003;6:273–7
   PubMed Web of Science ®Google Scholar
• Mirkin S, Archer DF. Effects of levonorgestrel, medroxyprogesterone acetate, norethindrone, progesterone, and 17beta-estradiol on thrombospondin-1 mRNA in Ishikawa cells. Fertil Steril 2004;82:220–2
   PubMed Web of Science ®Google Scholar
• Mirkin S, Wong BC, Archer DF. Effect of 17 beta-estradiol, progesterone, synthetic progestins, tibolone, and tibolone metabolites on vascular endothelial growth factor mRNA in breast cancer cells. Fertil Steril 2005;84:485–91
   PubMed Web of Science ®Google Scholar
• Mirkin S, Archer DF, Taylor HS, Pickar JH, Komm BS. Differential effects of menopausal therapies on the endometrium. Menopause 2014;21:899–908
   PubMed Web of Science ®Google Scholar
• Ryan N, Rosner A. Quality of life and costs associated with micronized progesterone and medroxyprogesterone acetate in hormone replacement therapy for nonhysterectomized, postmenopausal women. Clin Ther 2001;23:1099–115
   PubMed Web of Science ®Google Scholar
• Cummings JA, Brizendine L. Comparison of physical and emotional side effects of progesterone or medroxyprogesterone in early postmenopausal women. Menopause 2002;9:253–63
   PubMed Web of Science ®Google Scholar
• Gillet JY, Andre G, Faguer B, et al. Induction of amenorrhea during hormone replacement therapy: optimal micronized progesterone dose. A multicenter study. Maturitas 1994;19:103–15
   PubMed Web of Science ®Google Scholar
• Goldstein SR, Constantine G, Archer DF, et al. Effects of TX-001HR on uterine bleeding rates in menopausal women with vasomotor symptoms (S-18). 2017 NAMS Annual Meeting (Oct 11–14, 2017). Philadelphia, PA. 2017. Available from: http://www.menopause.org/docs/default-source/2017/2017-nams-scientific-and-poster-abs-tracts.pdf [last accessed 8 Dec 2017]
   Google Scholar
• Di Carlo C, Sammartino A, Di Spiezio SA, et al. Bleeding patterns during continuous estradiol with different sequential progestogens therapy. Menopause 2005;12:520–5
   PubMed Web of Science ®Google Scholar
• Di Carlo C, Tommaselli GA, Gargano V, Savoia F, Bifulco G, Nappi C. Transdermal estradiol and oral or vaginal natural progesterone: bleeding patterns. Climacteric 2010;13:442–6
   PubMed Web of Science ®Google Scholar
• Hitchcock CL, Prior JC. Oral micronized progesterone for vasomotor symptoms–a placebo-controlled randomized trial in healthy postmenopausal women. Menopause 2012;19:886–93
   PubMed Web of Science ®Google Scholar
• Greendale GA, Reboussin BA, Hogan P, et al. Symptom relief and side effects of postmenopausal hormones: results from the Postmenopausal Estrogen/Progestin Interventions Trial. Obstet Gynecol 1998;92:982–8
   PubMed Web of Science ®Google Scholar
• Montplaisir J, Lorrain J, Denesle R, Petit D. Sleep in menopause: differential effects of two forms of hormone replacement therapy. Menopause 2001;8:10–16
   PubMed Web of Science ®Google Scholar
• Gambacciani M, Ciaponi M, Cappagli B, et al. Effects of low-dose, continuous combined hormone replacement therapy on sleep in symptomatic postmenopausal women. Maturitas 2005;50:91–7
   PubMed Web of Science ®Google Scholar
• Simon J, Kaunitz A, Kroll R, Graham S, Bernick B, Mirkin S. TX-001HR improved quality of life in postmenopausal women with vasomotor symptoms (S-19). Menopause 2017;24:1432
   Web of Science ®Google Scholar
• Schussler P, Kluge M, Yassouridis A, et al. Progesterone reduces wakefulness in sleep EEG and has no effect on cognition in healthy postmenopausal women. Psychoneuroendocrinology 2008;33:1124–31
   PubMed Web of Science ®Google Scholar
• Kagan R, Constantine G, Kaunitz A, Gasper G, Bernick B, Mirkin S. TX-001HR improved the Medical Outcomes Study-Sleep (MOS-Sleep) questionnaire in menopausal women with vasomotor symptoms (S-17). Menopause 2017;24:1431
   Web of Science ®Google Scholar
• Writing Group for the Pepi Trial. Effects of hormone therapy on bone mineral density: results from the postmenopausal estrogen/progestin interventions (PEPI) trial. JAMA 1996;276:1389–96
   PubMed Web of Science ®Google Scholar
• Sun A, Lin S, Yu W, et al. Percutaneous estrogen in prevention of early postmenopausal bone loss in Chinese women. Chin Med J (Engl) 2002;115:1790–5
   PubMed Web of Science ®Google Scholar
• Farr JN, Khosla S, Miyabara Y, Miller VM, Kearns AE. Effects of estrogen with micronized progesterone on cortical and trabecular bone mass and microstructure in recently postmenopausal women. J Clin Endocrinol Metab 2013;98:E249–57
   PubMed Web of Science ®Google Scholar
• Prestwood KM, Kenny AM, Kleppinger A, Kulldorff M. Ultralow-dose micronized 17beta-estradiol and bone density and bone metabolism in older women: a randomized controlled trial. JAMA 2003;290:1042–8
   PubMed Web of Science ®Google Scholar
• Riis BJ, Thomsen K, Strom V, Christiansen C. The effect of percutaneous estradiol and natural progesterone on postmenopausal bone loss. Am J Obstet Gynecol 1987;156:61–5
   PubMed Web of Science ®Google Scholar
• Chang KJ, Lee TT, Linares-Cruz G, Fournier S, de Lignieres B. Influences of percutaneous administration of estradiol and progesterone on human breast epithelial cell cycle in vivo. Fertil Steril 1995;63:785–91
   PubMed Web of Science ®Google Scholar
• Foidart JM, Colin C, Denoo X, et al. Estradiol and progesterone regulate the proliferation of human breast epithelial cells. Fertil Steril 1998;69:963–9
   PubMed Web of Science ®Google Scholar
• Murkes D, Conner P, Leifland K, et al. Effects of percutaneous estradiol-oral progesterone versus oral conjugated equine estrogens-medroxyprogesterone acetate on breast cell proliferation and bcl-2 protein in healthy women. Fertil Steril 2011;95:1188–91
   PubMed Web of Science ®Google Scholar
• Murkes D, Lalitkumar PG, Leifland K, Lundstrom E, Soderqvist G. Percutaneous estradiol/oral micronized progesterone has less-adverse effects and different gene regulations than oral conjugated equine estrogens/medroxyprogesterone acetate in the breasts of healthy women in vivo. Gynecol Endocrinol 2012;28(Suppl 2):12–15
   PubMed Web of Science ®Google Scholar
• Crandall CJ, Aragaki AK, Cauley JA, et al. Breast tenderness and breast cancer risk in the estrogen plus progestin and estrogen-alone women’s health initiative clinical trials. Breast Cancer Res Treat 2012;132:275–85
   PubMed Web of Science ®Google Scholar
• Crandall CJ, Aragaki AK, Cauley JA, et al. Breast tenderness after initiation of conjugated equine estrogens and mammographic density change. Breast Cancer Res Treat 2012;131:969–79
   PubMed Web of Science ®Google Scholar
• Files JA, Miller VM, Cha SS, Pruthi S. Effects of different hormone therapies on breast pain in recently postmenopausal women: findings from the Mayo Clinic KEEPS breast pain ancillary study. J Womens Health (Larchmt) 2014;23:801–5
   PubMed Web of Science ®Google Scholar
• Crandall CJ, Karlamangla A, Huang MH, Ursin G, Guan M, Greendale GA. Association of new-onset breast discomfort with an increase in mammographic density during hormone therapy. Arch Intern Med 2006;166:1578–84
   PubMed Web of Science ®Google Scholar
• Fournier A, Mesrine S, Dossus L, Boutron-Ruault MC, Clavel-Chapelon F, Chabbert-Buffet N. Risk of breast cancer after stopping menopausal hormone therapy in the E3N cohort. Breast Cancer Res Treat 2014;145:535–43
   PubMed Web of Science ®Google Scholar
• Fournier A, Berrino F, Riboli E, Avenel V, Clavel-Chapelon F. Breast cancer risk in relation to different types of hormone replacement therapy in the E3N-EPIC cohort. Int J Cancer 2005;114:448–54
   PubMed Web of Science ®Google Scholar
• Fournier A, Berrino F, Clavel-Chapelon F. Unequal risks for breast cancer associated with different hormone replacement therapies: results from the E3N cohort study. Breast Cancer Res Treat 2008;107:103–11
   PubMed Web of Science ®Google Scholar
• Yang Z, Hu Y, Zhang J, Xu L, Zeng R, Kang D. Estradiol therapy and breast cancer risk in perimenopausal and postmenopausal women: a systematic review and meta-analysis. Gynecol Endocrinol 2017;33:87–92
   PubMed Web of Science ®Google Scholar
• Canonico M, Alhenc-Gelas M, Plu-Bureau G, Olie V, Scarabin PY. Activated protein C resistance among postmenopausal women using transdermal estrogens: importance of progestogen. Menopause 2010;17:1122–7
   PubMed Web of Science ®Google Scholar
• Harman SM, Black DM, Naftolin F, et al. Arterial imaging outcomes and cardiovascular risk factors in recently menopausal women. A Randomized Trial. Ann Intern Med 2014;161:249–60
   PubMed Web of Science ®Google Scholar
• Rosano GM, Webb CM, Chierchia S, et al. Natural progesterone, but not medroxyprogesterone acetate, enhances the beneficial effect of estrogen on exercise-induced myocardial ischemia in postmenopausal women. J Am Coll Cardiol 2000;36:215–19
   Web of Science ®Google Scholar
• Writing Group for the PEPI Trial. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) trial. JAMA 1995;273:199–208
   PubMed Web of Science ®Google Scholar
• Koh KK, Han SH, Shin MS, Ahn JY, Lee Y, Shin EK. Significant differential effects of lower doses of hormone therapy or tibolone on markers of cardiovascular disease in post-menopausal women: a randomized, double-blind, crossover study. Eur Heart J 2005;26:1362–8
   PubMed Web of Science ®Google Scholar
• Moorjani S, Dupont A, Labrie F, et al. Changes in plasma lipoprotein and apolipoprotein composition in relation to oral versus percutaneous administration of estrogen alone or in cyclic association with utrogestan in menopausal women. J Clin Endocrinol Metab 1991;73:373–9
   PubMed Web of Science ®Google Scholar
• Xue W, Deng Y, Wang YF, Sun AJ. Effect of half-dose and standard-dose conjugated equine estrogens combined with natural progesterone or dydrogesterone on components of metabolic syndrome in healthy postmenopausal women: a randomized controlled trial. Chin Med J (Engl) 2016;129:2773–9
   PubMed Web of Science ®Google Scholar
• Casanova G, Spritzer PM. Effects of micronized progesterone added to non-oral estradiol on lipids and cardiovascular risk factors in early postmenopause: a clinical trial. Lipids Health Dis 2012;11:133
   PubMed Web of Science ®Google Scholar
• Casanova G, dos Reis AM, Spritzer PM. Low-dose oral or non-oral hormone therapy: effects on C-reactive protein and atrial natriuretic peptide in menopause. Climacteric 2015;18:86–93
   PubMed Web of Science ®Google Scholar
• Suvanto-Luukkonen E, Sundstrom H, Penttinen J, Kauppila A. Lipid effects of an intrauterine levonorgestrel device or oral vs. vaginal natural progesterone in post-menopausal women treated with percutaneous estradiol. Arch Gynecol Obstet 1998;261:201–8
   PubMed Web of Science ®Google Scholar
• Kling JM, Lahr BA, Bailey KR, Harman SM, Miller VM, Mulvagh SL. Endothelial function in women of the kronos early estrogen prevention study. Climacteric 2015;18:187–97
   PubMed Web of Science ®Google Scholar
• Mather KJ, Norman EG, Prior JC, Elliott TG. Preserved forearm endothelial responses with acute exposure to progesterone: A randomized cross-over trial of 17-beta estradiol, progesterone, and 17-beta estradiol with progesterone in healthy menopausal women. J Clin Endocrinol Metab 2000;85:4644–9
   PubMed Web of Science ®Google Scholar
• Shifren JL, Rifai N, Desindes S, McIlwain M, Doros G, Mazer NA. A comparison of the short-term effects of oral conjugated equine estrogens versus transdermal estradiol on C-reactive protein, other serum markers of inflammation, and other hepatic proteins in naturally menopausal women. J Clin Endocrinol Metab 2008;93:1702–10
   PubMed Web of Science ®Google Scholar
• Bechlioulis A, Naka KK, Kalantaridou SN, et al. Short-term hormone therapy improves sCD40L and endothelial function in early menopausal women: potential role of estrogen receptor polymorphisms. Maturitas 2012;71:389–95
   PubMed Web of Science ®Google Scholar
• Otsuki M, Saito H, Xu X, et al. Progesterone, but not medroxyprogesterone, inhibits vascular cell adhesion molecule-1 expression in human vascular endothelial cells. Arterioscler Thromb Vasc Biol 2001;21:243–8
   PubMed Web of Science ®Google Scholar
• Piercy KT, Donnell RL, Kirkpatrick SS, et al. Effects of estrogen, progesterone, and combination exposure on interleukin-1 beta-induced expression of VCAM-1, ICAM-1, PECAM, and E-selectin by human female iliac artery endothelial cells. J Surg Res 2002;105:215–19
   PubMed Web of Science ®Google Scholar
• Henderson VW, St John JA, Hodis HN, et al. Cognitive effects of estradiol after menopause: a randomized trial of the timing hypothesis. Neurology 2016;87:699–708
   PubMed Web of Science ®Google Scholar
• Gleason CE, Dowling NM, Wharton W, et al. Effects of hormone therapy on cognition and mood in recently postmenopausal women: findings from the randomized, controlled KEEPS-cognitive and affective study. PLoS Med 2015;12:e1001833
   PubMed Web of Science ®Google Scholar
• Sherwin BB, Grigorova M. Differential effects of estrogen and micronized progesterone or medroxyprogesterone acetate on cognition in postmenopausal women. Fertil Steril 2011;96:399–403
   PubMed Web of Science ®Google Scholar